Skip to main content
NCBI home page
Molecules logoLink to Molecules
. 2021 Sep 13;26(18):5547. doi: 10.3390/molecules26185547

Nitropyridines as 2π-Partners in 1,3-Dipolar Cycloadditions with N-Methyl Azomethine Ylide: An Easy Access to Condensed Pyrrolines

Maxim A Bastrakov 1,*, Alexey K Fedorenko 1, Alexey M Starosotnikov 1, Alexander Kh Shakhnes 1
Editors: Alexander V Aksenov1, Fawaz Aldabbagh1
PMCID: PMC8471275  PMID: 34577019

Abstract

1,3-Dipolar cycloaddition reactions of 2-substituted 5-R-3-nitropyridines and isomeric 3-R-5-nitropyridines with N-methyl azomethine ylide were studied. The effect of the substituent at positions 2 and 5 of the pyridine ring on the possibility of the [3+2]-cycloaddition process was revealed. A number of new derivatives of pyrroline and pyrrolidine condensed with a pyridine ring were synthesized.

Keywords: nitro group; nitropyridines; pyrrolo[3,4-c]pyridines; dearomatization; 1,3-dipolar cycloadditition; pyrrolidines; azomethine ylides

1. Introduction

Pyridine derivatives of both natural and synthetic origin are one of the promising classes of heterocyclic compounds, which have a great synthetic potential and are of interest for the synthesis of biologically active substances. It is known that a large number of pyridine derivatives possess antimicrobial, antiviral, anticancer, analgesic, and antioxidant activities [1,2,3,4,5]. Recently, there has been a rapid development of approaches to the synthesis (including industrial) of condensed pyridines with various types of useful biological activity [6,7,8,9,10,11,12].

1,3-Dipolar cycloaddition reactions represent one of the most effective strategies leading to new fused heterocycles. Cycloaddition to aromatic compounds is accompanied by dearomatization, which leads to saturated, hardly accessible structures [13,14,15,16,17,18].

Earlier, we reported on the development of a method for the synthesis of pyrrolidine and pyrroline derivatives condensed with a pyridine ring on the basis of 2-R-3,5-dinitropyridines [19,20]. It was shown that, depending on the nature of 2-R, annulation of either two pyrrolidine rings or one pyrroline ring is possible [20], Scheme 1.

Scheme 1.

Scheme 1

Open in a new tab

Synthesis of pyrrolidine and pyrroline derivatives condensed with pyridine ring.

2. Results and Discussion

2.1. Synthesis of Starting 2-Substitutied 5-R-3nitropyridines 2a–q

In this work we studied the effect of the substituent at position 5 of the pyridine ring on the [3+2]-cycloaddition process. We used available 2-chloro-5-R-3-nitropyridines 1 as starting compounds. The mobile chlorine atom in these compounds is capable of being replaced by the action of nucleophiles under mild conditions. As a result of reaction 1 with thiols, amines, and phenols, compounds 2a–q were synthesized (Scheme 2, Table 1).

Scheme 2.

Scheme 2

Open in a new tab

Synthesis of nitropyridines 2a–q.

Table 1.

Reaction conditions and isolated yields of compounds 2a–q.

Compound R3H R1 R2 Conditions * Yield (%)
2a BnSH CF3 NO2 A 88
2b 4-NO2-C6H4OH CF3 NO2 B 79
2c graphic file with name molecules-26-05547-i001.jpg CF3 NO2 C 95
2d BnSH CO2Me NO2 A 95
2e 4-NO2-C6H4OH CO2Me NO2 B 93
2f graphic file with name molecules-26-05547-i002.jpg CO2Me NO2 C 92
2g i-BuSH CO2Me NO2 A 85
2h BnSH Cl NO2 A 77
2i 4-NO2-C6H4OH Cl NO2 B 81
2j graphic file with name molecules-26-05547-i003.jpg Cl NO2 C 91
2k BnSH Me NO2 A 58
2l BnSH Br NO2 A 68
2m 4-NO2-C6H4OH Br NO2 B 74
2n graphic file with name molecules-26-05547-i004.jpg Br NO2 C 86
2o BnSH NO2 CO2Me A 98
2p 4-NO2-C6H4OH NO2 CO2Me B 92
2q graphic file with name molecules-26-05547-i005.jpg NO2 CO2Me C 94
Open in a new tab

* Reaction conditions. A: R3H (1 equiv.), Et3N, MeOH, 20 °C; B: R3H (1 equiv.), Na2CO3, CH3CN, 80 °C; C: R3H (2 equiv.), MeOH, 20 °C.

2.2. [3+2]-Cycloaddition of Nitropyridines 2

We studied pyridines 2a–q in 1,3-dipolar cycloaddition reactions with an excess of N-methyl azomethine ylide 3, which was generated in situ from sarcosine and paraformaldehyde under reflux in toluene. In the case of pyridines 2a,b,d,e,g–i,k–m,o–q, a dipole was added at the C=C-NO2 bond followed by elimination of the HNO2 molecule and rearomatization of the system with the formation of pyrroline derivatives 4, Scheme 3.

Scheme 3.

Scheme 3

Open in a new tab

[3+2]-Cycloaddition of pyridines 2 with N-methyl azomethine ylide 3.

Thus, pyridines containing a donor substituent (Me or H) at position 5 do not undergo a [3+2]-cycloaddition reaction. In addition, in the presence of an amine moiety in position 2 (compounds 2c, 2j, 2n, 2q), the reaction also does not proceed. This reactivity is most likely associated with the electron-donor effect of the amino group, which reduces the overall electrophilicity of the starting compound [20,21]. The target product was isolated only for compound 2f where conversion of the starting pyridine was about 50% according to the NMR spectroscopy data.

The reaction of pyridine 2o with azomethine ylide 3 deserves special attention (Scheme 4). We found that this reaction resulted in the addition of two molecules of a dipole to the pyridine nucleus with the formation of compound 5.

Scheme 4.

Scheme 4

Open in a new tab

Reaction of 2o with N-methyl azomethine ylide.

It is known that, in similar reactions, the addition of a dipole occurs from the opposite sides of the benzene (pyridine) ring, providing trans-cycloadducts [19,20,22,23]. However there are examples of the formation of cis-cycloadducts [24]. The cycloaddition of 3 to pyridine 2o can in principle provide two isomeric products 5 and 6, Figure 1. We carried out a detailed study of the cycloaddition adduct using various NMR experiments (COSY, 1H-13C HMBC, 1H-13C HSQC, NOESY). The full assignment of hydrogen and carbon atoms in NMR spectra was made. The 1H-1H NOESY spectrum of 5 contains a characteristic cross-peak corresponding to the interaction of spatially close H(1) and H(6) protons, Figure 1. At the same time, the interaction between H(1) and H(5) was not observed. These data allowed us to unambiguously confirm trans-cycloaddition and the formation of compound 5.

Figure 1.

Figure 1

Open in a new tab

Selected interactions in 2D NOESY spectra of compound 5, 6.

3. Materials and Methods

3.1. General Information

All chemicals were of commercial grade and used directly without purification. Melting points were measured on a Stuart SMP 20 apparatus (Stuart (Bibby Scientific), UK). 1H and 13C NMR spectra were recorded on a Bruker AM-300 (at 300.13 and 75.13 MHz, respectively, Bruker Biospin, Germany) and a Bruker Avance DRX 500 (at 500 and 125 MHz, respectively, Bruker Biospin, Germany) in DMSO-d6 or CDCl3. HRMS spectra were recorded on a Bruker micrOTOF II mass spectrometer (Bruker micrOTOF II mass spectrometer) using ESI. All reactions were monitored by TLC analysis using ALUGRAM SIL G/UV254 plates, which were visualized by UV light (see Supplementary Materials).

3.2. Synthesis of Compounds 2a, 2d, 2g, 2h, 2k, 2l, 2o

An appropriate thiol (1 mmol) and Et3N (0.14 mL, 1 mmol) were added to a solution of 1 mmol of appropriate chloride in methanol (30 mL). The reaction mixture was stirred at room temperature for 0.5–2 h until the starting compound was completely consumed (TLC). Then mixture was poured into water and acidified with HCl to a pH of 4. The precipitate that formed was filtered off, washed with water, and dried in air.

2-(Benzylthio)-3-nitro-5-(trifluoromethyl)pyridine (2a). 88% M.p. 58–60 °C. 1H NMR (300 MHz, CDCl3): δ 4.54 (s, 2H, CH2), 7.30–7.46 (m, 5H, Ph), 8.73 (s, 1H.), 8.97 (s, 1H). NMR (75 MHz, CDCl3): δ 35.8, 120.8, 122.1, 122.5, 124.4, 127.6, 128.5, 128.7, 129.4, 131.1, 131.1, 136.0, 140.8, 149.2, 149.3, 162.1. HRMS (ESI) calc. for [C13H9F3N2O2S]+ [M + H]+ 315.0418, found 315.0410.

Methyl 6-(benzylthio)-5-nitronicotinate (2d). 95%. M.p. 103–105 °C. 1H NMR (300 MHz, CDCl3): δ 4.00 (s, 3H, CH3), 4.53 (s 2H, CH2), 7.26–7.44 (m, 5H, Ph), 8.01 (s, 1H.), 8.25 (s, 1H). 13C NMR (75 MHz, CDCl3): δ 35.8, 52.9, 121.8, 127.5, 128.6, 129.4, 134.4, 136.2, 141.1, 153.2, 162.3, 164.0. HRMS (ESI) calc. for [C14H12N2O4S]+ [M + H]+ 305.0590, found 305.0591.

Methyl 6-(isobutylthio)-5-nitronicotinate (2g). 85%. M.p. 64–66 °C. 1H NMR (300 MHz, CDCl3): δ 1.08 (d, J = 6.6 Hz, 6H, 2CH3(i-Bu)), 1.94–2.04 (m, 1H, CH (i-Bu)), 3.19 (d, J = 6,6 Hz, 2H, CH2 (i-Bu)), 3.99 (s, 2H, CO2CH3), 8.98 (s, 1H, C(4)-H), 9.20 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 22.2, 27.9, 39.4, 52.8, 121.2, 134.3, 141.6, 153.1, 163.2, 164.1. HRMS (ESI) calc. for [C11H14N2O4S]+ [M + H]+ 271.0751, found 271.0747.

2-(Benzylthio)-5-chloro-3-nitropyridine (2h). 77%. M.p. 65–67 °C. 1H NMR (300 MHz, CDCl3): δ 4.48 (s, 2H, CH2), 7.26–7.45 (m, 5H, Ph), 8.51 (d, J = 2.4 Hz, 1H, C(4)-H), 8.70 (d, J = 2.4 Hz, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 35.5, 127.0, 127.5, 128.6, 129.3, 133.1, 136.4, 141.3, 151.9, 155.9. HRMS (ESI) calc. for [C12H9ClN2O2S]+ [M + H]+ 281.0143, found 281.0146.

2-(Benzylthio)-5-methyl-3-nitropyridine (2k). 58%. M.p. 83–85 °C. 1H NMR (300 MHz, CDCl3): δ 2.43 (s, 3H, CH3), 4.48 (s, 2H, CH2), 7.25–7.45 (m, 5H, Ph), 8.32 (s, 1H), 8.58(s, 1H). 13C NMR (75 MHz, CDCl3): δ 17.3, 35.2, 127.2, 127.4, 128.5, 129.2, 129.4, 133.8, 137.1, 141.4, 153.8. HRMS (ESI) calc. for [C13H12N2O2S]+ [M + H]+ 261.0692, found 261.0687.

2-(Benzylthio)-5-bromo-3-nitropyridine (2l). 68%. M.p. 33–35 °C. 1H NMR (300 MHz, CDCl3): δ 4.38 (s, 2H, CH2), 7.18–7.37 (m, 5H, Ph), 8.56 (d, J = 2.1 Hz, 1H, C(4)-H), 8.70 (d, J = 2.1 Hz, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 35.5, 114.4, 127.5, 128.6, 129.4, 135.8, 136.4, 142.0, 154.0, 156.4. HRMS (ESI) calc.for [C12H9BrN2O2S]+ [M + H]+ 324.9639, found 324.9641.

Methyl 2-(benzylthio)-5-nitronicotinate (2o). 98%. M.p. 103–105 °C. 1H NMR (300 MHz, CDCl3): δ 3.91 (s, 3H, CH3), 4.44 (s, 2H, CH2), 7.16–7.37 (m, 5H, Ph), 8.88 (s, 1H), 8.30(s, 1H). 13C NMR (75 MHz, CDCl3): δ 35.8, 53.0, 122.1, 127.4, 128.6, 129.4, 133.5, 136.5, 140.2, 146.5, 163.9, 169.6. HRMS (ESI) calc. for [C14H12N2O4S]+ [M + H]+ 305.0592, found 305.0591.

3.3. Synthesis of Compounds 2b, 2e, 2i, 2m, 2p

4-Nitrophenol 0.14g (1 mmol) and Na2CO3 (0.106 g, 1 mmol) were added to a solution of appropriate chloride (1 mmol) in acetonitrile (15 mL). The reaction mixture was refluxed for 2 h until the starting compound was completely consumed (monitoring by TLC), poured into a five-fold excess of water, and acidified with HCl to a pH of 2. The precipitate that formed was filtered off, washed with water, and dried in air.

3-Nitro-2-(4-nitrophenoxy)-5-(trifluoromethyl)pyridine (2b). 79%. M.p. 96–98 °C. 1H NMR (300 MHz, CDCl3): δ 7.41 (d, J = 8.7 Hz, 2H, 4-NO2-Ph), 8.39 (d, J = 8.7 Hz, 2H, 4-NO2-Ph), 8.62 (s, 1H, C(4)-H), 8.69 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 120.3, 122.6, 122.9, 123.4, 123.9, 125.6, 133.7, 145.8, 148.8, 156.6. HRMS (ESI) calc. for [C12H6F3N3O5]+ [M + H]+ 330.0330, found 330.0332.

Methyl 5-nitro-6-(4-nitrophenoxy)nicotinate (2e). 93%. M.p. 128–130 °C. 1H NMR (300 MHz, CDCl3): δ 4.00 (s, 3H, CO2CH3), 7.39 (d, J = 9.0 Hz, 2H, 4-NO2-Ph), 8.36 (d, J = 9.0 Hz, 2H, 4-NO2-Ph), 8.93 (s, 1H, C(4)-H), 8.97 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 53.0, 122.6, 122.8, 125.9, 134.0, 136.9, 145.6, 152.9, 156.8, 163.2. HRMS (ESI) calc. for [C13H9N3O7]+ [M + H]+ 320.0503, found 320.0513.

5-Chloro-3-nitro-2-(4-nitrophenoxy)pyridine (2i). 81%. M.p. 110–112 °C. 1H NMR (300 MHz, CDCl3): δ 7.37 (d, J = 9.0 Hz, 2H, 4-NO2-Ph), 8.34–8.37 (m, 3H, C(4)-H и 4-NO2-Ph), 8.44 (d, J = 2.1 Hz, 1H, C(6)-H). 13C ЯMP (75 MHz, CDCl3): δ 122.2, 125.6, 126.9, 134.3, 135.4, 145.4, 150.2, 153.0, 157.2. HRMS (ESI) calc. for [C11H6ClN3O5]+ [M + H]+ 317.9882, found 317.9888.

5-Bromo-3-nitro-2-(4-nitrophenoxy)pyridine (2m). 74%. M.p. 118–120 °C. 1H NMR (300 MHz, CDCl3): δ 7.29 (d, J = 9.0 Hz, 2H, 4-NO2-Ph), 8.27 (d, J = 9.0 Hz, 2H, 4-NO2-Ph), 8.48 (d, J = 2.1 Hz, 1H, C(4)-H), 8.63 (d, J = 2.1 Hz, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 113.8, 122.2, 125.6, 138.1, 145.4, 152.4, 153.5, 157.2. HRMS (ESI) calc. for [C11H6BrN3O5]+ [M + H]+ 361.9379, found 361.9383.

Methyl 5-nitro-2-(4-nitrophenoxy)nicotinate (2p). 92%. M.p. 148–150 °C. 1H NMR (300 MHz, CDCl3): δ 3.96 (s, 3H, CO2CH3), 7.29 (d, J = 8.7 Hz, 2H, 4-NO2-Ph), 8.28 (d, J = 8.7 Hz, 2H, 4-NO2-Ph), 9.01 (s, 2H, C(4)-H и C(6)-H). 13C NMR (75 MHz, CDCl3): δ 53.3, 115.3, 122.6, 125.6, 137.6, 140.5, 145.5, 147.0, 157.3, 162.6, 163.3. HRMS (ESI) calc for [C13H9N3O7]+ [M + H]+ 320.0505, found 320.0513.

3.4. Synthesis of Compounds 2c, 2f, 2j, 2n, 2q

Pyrrolidine 0.16 mL (2 mmol) was added to a solution of appropriate chloride (1 mmol) in methanol (15 mL). The reaction mixture was stirred at room temperature for 2 h (monitoring by TLC), poured into an excess of water, and acidified with HCl to a pH of 2. The precipitate that formed was filtered off, washed with water, and dried.

3-Nitro-2-(pyrrolidin-1-yl)-5-(trifluoromethyl)pyridine (2c) 95%. M.p. 65–67 °C. 1H NMR (300 MHz, CDCl3): δ 2.04 (t, J = 6.6 Hz, 4H, CH2CH2CH2CH2), 3.47 (br.s, 4H, CH2CH2CH2CH2), 8.31 (s, 1H, C(4)-H), 8.55 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 25.3, 49.8, 113.5, 114.0, 121.7, 125.4, 130.1, 132.4, 132.5, 148.5, 148.6, 151.0. HRMS (ESI) calc. for [C10H10F3N3O2]+ [M + H]+ 262.0797, found 262.0798.

Methyl 5-nitro-6-(pyrrolidin-1-yl)nicotinate (2f). 92%. M.p. 87–89 °C. 1H NMR (300 MHz, CDCl3): δ 2.01 (br.s, 4H, CH2CH2CH2CH2), 3.48 (br.s, 4H, CH2CH2CH2CH2), 3.91 (s, 3H, CO2CH3), 8.62 (s, 1H, C(4)-H), 8.88 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 25.3, 49.8, 52.1, 113.6, 130.7, 136.1, 151.3, 153.1, 164.9. HRMS (ESI) calc. for [C11H13N3O4]+ [M + H]+ 252.0978, found 252.0689.

5-Chloro-3-nitro-2-(pyrrolidin-1-yl)pyridine (2j). 91%. M.p. 73–75 °C. 1H NMR (300 MHz, CDCl3): δ 1.98–2.05 (m, 4H, CH2CH2CH2CH2), 3.40 (t, J = 6.6 Hz, 4H, CH2CH2CH2CH2), 8.09 (d, J = 2.4 Hz, 1H, C(4)-H), 8.29 (d, J = 2.4 Hz, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 25.4, 49.7, 117.0, 130.8, 133.8, 148.8, 150.5. HRMS (ESI) calc. for [C9H10ClN3O2]+ [M + H]+ 228.0534, found 228.0534.

5-Bromo-3-nitro-2-(pyrrolidin-1-yl)pyridine (2n): 86%. M.p. 67–69 °C. 1H NMR (300 MHz, CDCl3): δ 1.92 (dd, J1 = 12.3 Hz, J2 = 6.6 Hz, 4H, CH2CH2CH2CH2), 3.31 (t, J = 6.6 Hz, 4H, CH2CH2CH2CH2), 8.13 (d, J = 2.1 Hz, 1H, C(4)-H), 8.27 (d, J = 2.1 Hz, 1H, C(6)-H). 13C ЯMP (75 MHz, CDCl3): δ 25.4, 49.7, 103.5, 136.4, 149.0, 152.5. HRMS (ESI) calc. for [C9H10BrN3O2]+ [M + H]+ 272.0029, found 272.0026.

Methyl 5-nitro-2-(pyrrolidin-1-yl)nicotinate (2q): 79%. M.p. 96–98 °C. 1H NMR (300 MHz, CDCl3): δ 1.93 (br.s, 4H, CH2CH2CH2CH2), 3.45 (br.s, 4H, CH2CH2CH2CH2), 3.85 (s, 3H, CO2CH3), 8.57 (d, J = 2.1 Hz, 1H, C(4)-H), 9.00 (d, J = 2.1 Hz, C(6)-H). 13C ЯMP (75 MHz, CDCl3): δ 25.4, 50.4, 52.7, 108.9, 133.8, 135.5, 147.5, 156.6, 165.9. HRMS (ESI) calc. for [C12H6F3N3O5]+ [M + H]+ 330.0330, found 330.0332.

3.5. Synthesis of Compounds 4a–j, 5

A mixture of an appropriate nitropyridine (1 mmol), paraformaldehyde (0.18 g, 6 mmol), and sarcosine (0.50 g, 6 mmol) was refluxed in toluene (30 mL), until the starting compound was completely consumed (TLC), and the mixture was cooled to room temperature and filtered. The solvent was evaporated under reduced pressure, and the residue was washed with hexane. The precipitate was filtered off. For compound 5, the residue was purified by column chromatography on MN Kieselgel 60 (0.04–0.063 mm/230–400 mesh) using EtOAc:MeOH (10:1) as an eluent.

4-(Benzylthio)-2-methyl-7-(trifluoromethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine (4a). 59%. M.p. 56–58 °C. 1H NMR (300 MHz, CDCl3): δ 2.61 (s, 3H, N-CH3), 3.85 (s, 2H, N-CH2), 4.08 (s, 2H, N-CH2), 4.56 (s, 2H, S-CH2), 7.24–7.45 (m, 5H, Ph), 8.57 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 33.6, 42.0, 58.1, 59.7, 117.0, 117.4, 117.8, 118.3, 118.6, 122.2, 125.9, 127.3, 128.6, 129.1, 129.5, 134.3, 137.6, 144.4, 144.5, 144.5, 144.6, 147.1, 157.0. HRMS (ESI) calc. for [C16H15F3N2S]+ [M + H]+ 325.0981, found 325.0984.

2-Methyl-4-(4-nitrophenoxy)-7-(trifluoromethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine (4b). 73%. M.p. 91–93 °C. 1H NMR (300 MHz, CDCl3): δ 2.68 (s, 3H, N-CH3), 4.09 (s, 2H, N-CH2), 4.17 (s, 2H, N-CH2), 7.34 (d, J = 9.0 Hz, 2H, 4-NO2-Ph), 8.28 (s, 1H, C(6)-H), 8.33 (d, J = 9.0 Hz, 2H, 4-NO2-Ph). 13C NMR (75 MHz, CDCl3): δ 41.9, 57.0, 59.9, 121.8, 125.2, 125.5, 143.6, 143.7, 143.8, 144.7, 153.0, 158.1, 159.0. HRMS (ESI) calc. for [C15H12F3N3O3]+ [M + H]+ 340.0904, found 340.0902.

Methyl 4-(benzylthio)-2-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carboxylate (4c). 64%. M.p. 93–95 °C. 1H NMR (300 MHz, CDCl3): δ 2.59 (s, 3H, N-CH3), 3.83 (s, 2H, N-CH2), 3.91 (s, 3H, CO2CH3), 4.24 (s, 2H, N-CH2), 4.56 (s, 2H, S-CH2), 7.21–7.42 (m, 5H, Ph), 8.92 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 33.6, 42.2, 45.4, 58.2, 61.8, 117.5, 127.3, 128.5, 129.1, 133.8, 137.7, 149.6, 151.0, 157.2, 166.0. HRMS (ESI) calc. for [C17H18N2O2S]+ [M + H]+ 315.1162, found 315.1172.

Methyl 2-methyl-4-(4-nitrophenoxy)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carboxylate (4d). 40%. M.p. 101–103 °C. 1H NMR (300 MHz, CDCl3): δ 2.66 (s, 3H, N-CH3), 3.92 (s, 3H, CO2CH3), 4.05 (s, 2H, N-CH2), 4.33 (s, 2H, N-CH2), 7.31 J = 8.1 Hz, 2H, 4-NO2-Ph), 8.29 (d, J = 8.1 Hz, 2H, 4-NO2-Ph), 8.65 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 29.7, 42.1, 52.2, 57.0, 61.9, 118.4, 121.6, 124.5, 125.5, 144.6, 149.2, 156.9, 158.3, 159.2, 165.1. HRMS (ESI) calc. for [C16H15N3O5]+ [M + H]+ 330.1084, found 330.1079.

Methyl 2-methyl-4-(pyrrolidin-1-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carboxylate (4e). 32%. M.p. 98–100 °C. 1H NMR (300 MHz, CDCl3): δ 1.94 (t, J = 6.6 Hz, 4H, CH2CH2CH2CH2), 2.59 (s, 3H, N-CH3), 3.65 (t, J = 6.6 Hz, 4H, CH2CH2CH2CH2), 3.82 (s, 3H, CO2CH3), 4.15 (d, J = 3.6 Hz, 4H, CH2-N-CH2), 8.62 (s, 1H, C(6)-H). 13C ЯMP (75 MHz, CDCl3): δ 25.4, 42.3, 48.1, 51.3, 60.6, 61.4, 110.1, 117.8, 150.4, 152.6, 155.5, 166.6. HRMS (ESI) calc. for [C14H19N3O2]+ [M + H]+ 262.1550, found 262.1556.

Methyl 4-(isobutylthio)-2-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carboxylate (4f). 54%. Oil. 1H NMR (300 MHz, CDCl3): δ 1.40 (d, J = 6.6 Hz, 6H, 2CH3(i-Bu)), 1.89–2.00 (m, 1H, CH (i-Bu)), 2.61 (s, 3H, N-CH3), 3.20 (d, J = 6,6 Hz, 2H, CH2 (i-Bu)), 3.86 (s, 2H, N-CH2), 3.90 (s, 3H, CO2CH3), 4.24 (s, 2H, N-CH2), 8.87 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 21.9, 28.6, 28.7, 37.2, 37.7, 37.9, 42.2, 51.6, 51.9, 58.3, 61.8, 112.1, 117.0, 141.7, 149.6, 150.5, 166.0. HRMS (ESI) calc. for [C14H20N2O2S]+ [M + H]+ 281.1318, found 281.1384.

4-(Benzylthio)-7-chloro-2-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine (4g). 45%. M.p. 70–72 °C. 1H NMR (300 MHz, CDCl3): δ 2.59 (s, 3H, N-CH3), 3.88 (s, 2H, N-CH2), 3.99 (s, 2H, N-CH2), 4.49 (s, 2H, S-CH2), 7.22–7.41 (m, 5H, Ph), 8.29 (s, 1H, C(6)-H). 13C NMR (125 MHz, CDCl3): δ 33.9, 42.1, 59.2, 59.9, 123.0, 127.1, 128.4, 129.0, 134.9, 137.9, 146.4, 147.5, 150.2. HRMS (ESI) calc. for [C15H15ClN2S]+ [M + H]+ 291.0717, found 291.0718.

7-Chloro-2-methyl-4-(4-nitrophenoxy)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine (4h). 37%. M.p. 119–121 °C. 1H NMR (300 MHz, CDCl3): δ 2.65 (s, 3H, N-CH3), 4.07 (s, 4H, CH2-N-CH2), 7.26 (d, J = 9.0 Hz, 2H, 4-NO2-Ph), 8.00 (s, 1H, C(6)-H), 8.29 (d, J = 9.0 Hz, 2H, 4-NO2-Ph). 13C ЯMP (125 MHz, CDCl3): δ 42.0, 58.1, 60.0, 120.7, 122.6, 125.5, 125.9, 144.1, 144.6, 152.8, 155.0, 159.0. HRMS (ESI) calc. for [C14H12ClN3O3]+ [M + H]+ 306.0639, found 306.0639.

4-(Benzylthio)-7-bromo-2-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine (4i). 47%. Oil. 1H NMR (300 MHz, CDCl3): δ 2.63 (s, 3H, N-CH3), 4.00 (s, 2H, N-CH2), 4.05 (s, 2H, N-CH2), 4.41 (s, 2H, S-CH2), 7.17–7.32 (m, 5H, Ph), 8.35 (s, 1H, C(6)-H). 13C NMR (75 MHz, CDCl3): δ 33.9, 42.2, 59.4, 61.5, 111.5, 127.2, 128.5, 129.0, 129.3, 134.8, 137.9, 148.7, 149.4, 151.0. HRMS (ESI) calc. for [C15H15BrN2S]+ [M + H]+ 335.0206, found 335.0212.

7-Bromo-2-methyl-4-(4-nitrophenoxy)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine (4j). 48%. M.p. 108–110 °C. 1H NMR (300 MHz, CDCl3): δ 2.67 (s, 3H, N-CH3), 4.07 (s, 2H, N-CH2), 4.14 (s, 2H, N-CH2), 7.26 (d, J = 9.0 Hz, 2H, 4-NO2-Ph), 8.10 (s, 1H, C(6)-H), 8.28 (d, J = 9.0 Hz, 2H, 4-NO2-Ph). 13C NMR (75 MHz, CDCl3): δ 42.1, 58.3, 61.7, 110.6, 120.9, 125.6, 144.3, 147.1, 154.5, 155.8, 158.9. HRMS (ESI) calc. for [C14H12BrN3O3]+ [M + H]+ 350.0134, found 350.0128.

Methyl (3aR,5aR,8aS,8bR)-5-(benzylthio)-2,7-dimethyl-8b-nitro-2,3,3a,6,7,8,8a,8b-octahydrodipyrrolo[3,4-b:3′,4′-d]pyridine-5a(1H)-carboxylate (5). 55%. Oil. Rf = 0.6. 1H NMR (300 MHz, CDCl3): δ 2.19–2.25 (m, 1H), 2.27 (s, 3H, N-CH3), 2.28 (s, 3H, N-CH3), 2.51 (d, J = 9.9 Hz, 1H), 2.53 (d, J = 10.0 Hz, 1H), 2.74 (t, J = 8.6 Hz, 1H), 2.99 (d, J = 11.0 Hz, 1H), 3.32–3.39 (m, 2H), 3.58–3.67 (m, 2H), 3.77 (s, 3H, CO2CH3), 4.12 (d, J = 13.8 Hz, 1H), 4.24 (d, J = 13.8 Hz, 1H), 4.94 (dd, J1 = 5.2 Hz, J2 = 2.2 Hz, 1H), 7.21–7.35 (m, 5H, Ph). 13C NMR (75 MHz, CDCl3): δ 34.1, 41.3, 41.5, 43.3, 53.2, 58.5, 58.8, 60.3, 62.5, 62.6, 66.0, 94.2, 127.1, 128.4, 129.0, 129.4, 137.4, 160.2, 170.9. HRMS (ESI) calc. for [C20H26N4O4S]+ [M + H]+ 419.1747, found 419.1747.

4. Conclusions

Thus, we showed that 2-substituted 5-R-3-nitropyridines and isomeric 3-R-5-nitropyridines can act as dipolarophiles in [3+2]-cycloaddition reactions with N-methyl azomethine ylide. The possibility and rate of the process depends on the combination of substituents at positions 2 and 5: the presence of electron-withdrawing groups is required. As a result, a number of new functionally complex derivatives of pyrroline and pyrrolidine condensed with a pyridine ring were synthesized.

Supplementary Materials

The following are available online, NMR spectra, HRMS data.

Click here for additional data file. (1.9MB, zip)

Author Contributions

All authors discussed, commented on, and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are not available from the authors.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Altaf A.A., Shahzad A., Gul Z., Rasool N., Badshah A., Lal B., Khan E. A Review on the Medical Importnace of Pyridine Derivatives. J. Drug Des. Med. Chem. 2015;1:1–11. doi: 10.11648/j.jddmc.20150101.11. [DOI] [Google Scholar]
  • 2.McAteer C.H., Balasubramanian M., Murugan R. In: Comprehensive Heterocyclic Chemistry III. Karitzky A.R., Ramsden C.A., Scriven E.F.V., Taylor R.J.K., Jones G., editors. Volume 7. Elsevier; New York, NY, USA: 2008. p. 309. [Google Scholar]
  • 3.Khan E. Pyridine Derivatives as Biologically Active Precursors; Organics and Selected Coordination Complexes. ChemistrySelect. 2021;6:3041–3064. doi: 10.1002/slct.202100332. [DOI] [Google Scholar]
  • 4.Jarman M., Barrie A.S.E., Llera† J.M. The 16,17-Double Bond Is Needed for Irreversible Inhibition of Human Cytochrome P45017α by Abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and Related Steroidal Inhibitors. J. Med. Chem. 1998;41:5375–5381. doi: 10.1021/jm981017j. [DOI] [PubMed] [Google Scholar]
  • 5.Guarna A., Occhiato E.G., Machetti F., Giacomelli V. 19-Nor-10-azasteroids. 5.1A Synthetic Strategy for the Preparation of (+)-17-(3-Pyridyl)-(5β)-10-azaestra-1,16-dien-3-one, a Novel Potential Inhibitor for Human Cytochrome P45017α(17α-Hydroxylase/C17,20-lyase) J. Org. Chem. 1999;64:4985–4989. doi: 10.1021/jo990373m. [DOI] [PubMed] [Google Scholar]
  • 6.Paget S.D., Foleno B.D., Boggs C.M., Goldschmidt R.M., Hlasta D.J., Weidner-Wells M.A., Werblood H.M., Wira E., Bush K., Macielag M.J. Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones. Bioorg. Med. Chem. Lett. 2003;13:4173–4177. doi: 10.1016/j.bmcl.2003.08.031. [DOI] [PubMed] [Google Scholar]
  • 7.Catalano J.G., Gudmundsson K.S., Svolto A., Boggs S.D., Miller J.F., Spaltenstein A., Thomson M., Wheelan P., Minick D.J., Phelps D.P., et al. Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1. Bioorg. Med. Chem. Lett. 2010;20:2186–2190. doi: 10.1016/j.bmcl.2010.02.030. [DOI] [PubMed] [Google Scholar]
  • 8.Horne D.B., Tamayo N.A., Bartberger M.D., Bo Y., Clarine J., Davis C.D., Gore V.K., Kaller M.R., Lehto S.G., Ma V.V., et al. Optimization of Potency and Pharmacokinetic Properties of Tetrahydroisoquinoline Transient Receptor Potential Melastatin 8 (TRPM8) Antagonists. J. Med. Chem. 2014;57:2989–3004. doi: 10.1021/jm401955h. [DOI] [PubMed] [Google Scholar]
  • 9.Kubo K., Ito N., Souzo I., Isomura Y., Homma H., Murakami M. Nitrogen-containing heterocyclic ring derivatives. 4284778 (A) U.S. Patent. 1981 August 18;
  • 10.Koeckritz P., Liebscher J., Huebler D. Verfahren zur herstellung von 1.2.4-Triazolo/1.5-a/-pyridin-8-carbonitrilen. DD280110 (A1) Ger. Patent. 1990 June 27;
  • 11.Guba W., Nettekoven M., Püllmann B., Riemer C., Schmitt S. Comparison of inhibitory activity of isomeric triazolopyridine derivatives towards adenosine receptor subtypes or do similar structures reveal similar bioactivities? Bioorg. Med. Chem. Lett. 2004;14:3307–3312. doi: 10.1016/j.bmcl.2004.03.104. [DOI] [PubMed] [Google Scholar]
  • 12.Selby T.P. Substituted phenyltriazolopyrimidine herbicides. 9012012. WO Patent. 1990 October 18;
  • 13.Bertuzzi G., Bernardi L., Fochi M. Nucleophilic Dearomatization of Activated Pyridines. Catalysts. 2018;8:632. doi: 10.3390/catal8120632. [DOI] [Google Scholar]
  • 14.Ramachandran G., Sathiyanarayanan K. Dearomatization Strategies of Heteroaromatic Compounds. Curr. Organocatal. 2015;2:14–26. doi: 10.2174/2213337201666141110222735. [DOI] [Google Scholar]
  • 15.Dudnik A.S., Weidner V.L., Motta A., Delferro M., Marks T.J. Atom-efficient regioselective 1, 2-dearomatization of functionalized pyridines by an earth-abundant organolanthanide catalyst. Nat. Chem. 2014;6:1100–1107. doi: 10.1038/nchem.2087. [DOI] [PubMed] [Google Scholar]
  • 16.Roche S.P., Porco J.A. Dearomatization Strategies in the Synthesis of Complex Natural Products. Angew. Chem. Int. Ed. 2011;50:4068–4093. doi: 10.1002/anie.201006017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Smith P.L., Chordia M., Harman W.D. Synthetic applications of the dearomatization agent pentaammineosmium(II) Tetrahedron. 2001;57:8203–8225. doi: 10.1016/S0040-4020(01)00805-5. [DOI] [Google Scholar]
  • 18.Wertjes W.C., Southgate E.H., Sarlah D. Recent advances in chemical dearomatization of nonactivated arenes. Chem. Soc. Rev. 2018;47:7996–8017. doi: 10.1039/C8CS00389K. [DOI] [PubMed] [Google Scholar]
  • 19.Bastrakov M.A., Kucherova A.Y., Fedorenko A.K., Starosotnikov A.M., Fedyanin I.V., Dalinger I.L., Shevelev S.A. Dearomatization of 3,5-dinitropyridines–an atom-efficient approach to fused 3-nitropyrrolidines. Arkivoc. 2017;2017:181–190. doi: 10.24820/ark.5550190.p010.185. [DOI] [Google Scholar]
  • 20.Bastrakov M.A., Fedorenko A.K., Starosotnikov A.M., Kachala V.V., Shevelev S.A. Dearomative (3+2) cycloaddition of 2-substituted 3,5-dinitropyridines and N-methyl azomethine ylide. Chem. Heterocycl. Compd. 2019;55:72–77. doi: 10.1007/s10593-019-02421-9. [DOI] [Google Scholar]
  • 21.Hansch C., Leo A., Taft R.W. A survey of Hammett substituent constants and resonance and field parameters. Chem. Rev. 1991;91:165–195. doi: 10.1021/cr00002a004. [DOI] [Google Scholar]
  • 22.Bastrakov M.A., Starosotnikov A.M., Pechenkin S.Y., Kachala V.V., Glukhov I.V., Shevelev S.A. Double 1,3-dipolar cycloaddition of N-methyl Azomethine ylide to meta-Dinitrobenzene annelated with nitrogen aromatic heterocycles. J. Heterocycl. Chem. 2010;47:893–896. doi: 10.1002/jhet.423. [DOI] [Google Scholar]
  • 23.Konstantinova L.S., Bastrakov M.A., Starosotnikov A.M., Glukhov I.V., Lysov K.A., Rakitin O.A., Shevelev S.A. 4,6-Dinitrobenzo[c]isothiazole: Synthesis and 1,3-dipolar cycloaddition to azomethine ylide. Mendeleev Commun. 2010;20:353–354. doi: 10.1016/j.mencom.2010.11.018. [DOI] [Google Scholar]
  • 24.Lee S., Diab S., Queval P., Sebban M., Chataigner I., Piettre S.R. Aromatic C=C Bonds as Dipolarophiles: Facile Reactions of Uncomplexed Electron-Deficient Benzene Derivatives and Other Aromatic Rings with a Non-Stabilized Azomethine Ylide. Chem. Eur. J. 2013;19:7181–7192. doi: 10.1002/chem.201201238. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (1.9MB, zip)

Data Availability Statement

Not applicable.

Articles from Molecules are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES